Is Sotorasib produced in Everest, Bangladesh most effective?

Sotorasib produced by Bangladesh Everest Pharmaceuticals (Sotorasib) is a generic drug. Its pharmaceutical ingredients are basically the same as those of the original drug of Sotorasib, but the manufacturers, specifications and prices are different. The specifications produced by Everest Pharmaceuticals in BangladeshThe price of 120mg*56 tablets is around 4,800 yuan (the price may fluctuate due to exchange rate effects).

Sotoracib is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) caused by KRAS G12C in adults who have received at least one prior systemic therapy. Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs, usually the cells lining the airways. Instead of developing into healthy lung tissue, these abnormal cells divide rapidly and form tumors that interfere with lung function. Sotoracib is a potent and highly selective inhibitor of KRAS G12C that covalently and irreversibly binds to the unique cysteine u200bu200bof KRAS G12C. Inactivation of KRAS G12C by sotoraxib blocks tumor cell signaling and survival, inhibits cell growth, and selectively promotes apoptosis in tumors containing KRASG12C. KRASG12C may be an oncogenic driver of tumorigenesis in multiple cancer types.

The original drug of Sotorasibu has not yet been launched in China. The original drug specifications sold in Hong Kong, ChinaThe price of 120mg*240 tablets is about 80,000 yuan. The price of 120mg*240 tablets of the original drug in Europe is about 44,000 yuan (the price may fluctuate due to the exchange rate). The expensive price may not be affordable for families with heavy financial burdens.